Hyperion Therapeutics Announces Pricing of Follow-On Offering

Hyperion Therapeutics Announces Pricing of Follow-On Offering

SOUTH SAN FRANCISCO, Calif., March 8, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics, Inc. (Nasdaq:HPTX) announced today the pricing of its follow-on
offering of 2,875,000 shares of its common stock at $20.75 per share, before
underwriting discounts and commissions. All of the common stock is being
offered by Hyperion. In addition, the underwriters have a 30-day option to
purchase up to an additional 431,250 shares of common stock from Hyperion to
cover over-allotments, if any. The offering is expected to close on March 13,
2013, subject to customary closing conditions.

Leerink Swann LLC and Cowen and Company, LLC are serving as joint book-running
managers for the proposed offering. Needham & Company, LLC and JMP Securities
LLC are acting as co-managers for the proposed offering.

A registration statement relating to these securities was declared effective
by the Securities and Exchange Commission on March 7, 2013. This offering is
being made only by means of a prospectus, copies of which may be obtained from
Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA 02110, by calling (800) 808-7525, ext. 4814, and Cowen and
Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Attn: Prospectus Department, by calling (631) 274-2806, or
faxing (631) 254-7140.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or other jurisdiction.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. For more information, please visit

CONTACT: Shari Annes, Investor Relations
         (650) 888-0902
         Kristie Kuhl, Media Relations
         (203) 556-7417
Press spacebar to pause and continue. Press esc to stop.